RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC)
Definition
rhAPC has been shown to decrease mortality in severely septic patients in some clinical trials. There are a number of clinical criteria applied to patients to determine eligibility best captured in a standardized ICU policy for administration.
Compliance with this bundle element is defined as the percent of patients with severe sepsis or septic shock for whom rhAPC was administerred in accordance with a standardized ICU policy within 24 hours following the time of presentation.
Note: It is possible that the standardized ICU policy that governs Drotrecogin Alfa (Activated) administration concludes that the drug should not be given in a particular case. In that case, as long as there is annotation in the chart concluding that Drotrecogin Alfa was not indicated by protocol, simply assign credit for following the policy.
Exclusion: Non-severe sepsis
Goal
Increase administration of rhAPC in accordance with a standardized ICU policy to 100 percent of indicated severe sepsis cases.
Related Changes
Administer rhAPC by a Standard Policy
Sample Graph
Use IHI's Improvement Tracker to enter, save, and graph your team's data.